Erlotinib, another FDA approved EGFR TKi used in the treatment of NSCLC malignancies, resulted in a very similar mutational profile compared to gefitinib, which agrees with pervious published data74. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.